Rezolute公司透露，美国食品药品监督管理局（FDA）目前尚未完成对该公司提交的关于Ersodetug在先天性高胰岛素血症治疗领域监管路径的审评工作。这一消息意味着，该药物的未来走向仍悬而未决，监管层面的最终决定尚需时日。
Rezolute公司透露，美国食品药品监督管理局（FDA）目前尚未完成对该公司提交的关于Ersodetug在先天性高胰岛素血症治疗领域监管路径的审评工作。这一消息意味着，该药物的未来走向仍悬而未决，监管层面的最终决定尚需时日。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.